NASDAQ:CCCC C4 Therapeutics (CCCC) Stock Price, News & Analysis → The biggest energy story ever? (From Porter & Company) (Ad) Free CCCC Stock Alerts $6.54 +0.24 (+3.81%) (As of 05:27 PM ET) Add Compare Share Share Today's Range$6.22▼$6.6150-Day Range$6.17▼$11.0052-Week Range$1.06▼$11.88Volume1.81 million shsAverage Volume3.48 million shsMarket Capitalization$448.65 millionP/E RatioN/ADividend YieldN/APrice Target$10.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get C4 Therapeutics alerts: Email Address C4 Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside59.4% Upside$10.25 Price TargetShort InterestBearish13.94% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.36Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.86) to ($2.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.08 out of 5 starsMedical Sector836th out of 919 stocksBiological Products, Except Diagnostic Industry135th out of 148 stocks 3.3 Analyst's Opinion Consensus RatingC4 Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageC4 Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted13.94% of the outstanding shares of C4 Therapeutics have been sold short.Short Interest Ratio / Days to CoverC4 Therapeutics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in C4 Therapeutics has recently increased by 4.48%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldC4 Therapeutics does not currently pay a dividend.Dividend GrowthC4 Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CCCC. Previous Next 1.3 News and Social Media Coverage News SentimentC4 Therapeutics has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for C4 Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 17 people have searched for CCCC on MarketBeat in the last 30 days. This is a decrease of -15% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added C4 Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, C4 Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.97% of the stock of C4 Therapeutics is held by insiders.Percentage Held by Institutions78.81% of the stock of C4 Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for C4 Therapeutics are expected to decrease in the coming year, from ($1.86) to ($2.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of C4 Therapeutics is -2.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of C4 Therapeutics is -2.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioC4 Therapeutics has a P/B Ratio of 1.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceHave You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...This strange new device to protect us against that A.I. threat... About C4 Therapeutics Stock (NASDAQ:CCCC)C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Read More CCCC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CCCC Stock News HeadlinesApril 30, 2024 | finanznachrichten.deC4 Therapeutics, Inc.: C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 29, 2024 | globenewswire.comC4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 1, 2024 | Porter & Company (Ad)Trump’s last act as President You’ve probably never heard of Executive Order #13972. Signed by President Trump just days before leaving office, it greenlit what could be the most revolutionary technology of the decade… yet it has nothing to do with AI, blockchain, or mRNA vaccines. April 11, 2024 | seekingalpha.comArvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win SituationApril 9, 2024 | globenewswire.comC4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology ForumApril 8, 2024 | msn.comC4 Dips on Release of DataApril 8, 2024 | finance.yahoo.comC4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024April 8, 2024 | globenewswire.comC4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024May 1, 2024 | Porter & Company (Ad)Trump’s last act as President You’ve probably never heard of Executive Order #13972. Signed by President Trump just days before leaving office, it greenlit what could be the most revolutionary technology of the decade… yet it has nothing to do with AI, blockchain, or mRNA vaccines. March 28, 2024 | finance.yahoo.comHere’s Why Meridian Small Cap Growth Fund Trimmed C4 Therapeutics (CCCC)March 16, 2024 | finance.yahoo.comCCCC Mar 2024 17.000 callMarch 16, 2024 | finance.yahoo.comCCCC Mar 2024 10.000 putMarch 9, 2024 | nasdaq.comGuru Fundamental Report for CCCCMarch 5, 2024 | globenewswire.comC4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024March 4, 2024 | globenewswire.comC4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic ProteinsMarch 2, 2024 | finance.yahoo.comCCCC Mar 2024 9.000 callMarch 1, 2024 | seekingalpha.comC4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains StretchedFebruary 27, 2024 | finance.yahoo.comNew Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)February 26, 2024 | markets.businessinsider.comBreaking Down C4 Therapeutics: 4 Analysts Share Their ViewsFebruary 25, 2024 | finance.yahoo.comCCCC Mar 2024 8.500 putFebruary 24, 2024 | ca.finance.yahoo.comCCCC Mar 2024 7.000 putFebruary 24, 2024 | finance.yahoo.comC4 Therapeutics Full Year 2023 Earnings: Misses ExpectationsFebruary 23, 2024 | markets.businessinsider.comStrong Financials and Promising Drug Pipeline Bolster Buy Rating for C4 TherapeuticsFebruary 23, 2024 | realmoney.thestreet.comC4 Therapeutics price target raised by $1 at Stifel, here's whyFebruary 22, 2024 | benzinga.comC4 Therapeutics Stock (NASDAQ:CCCC) Insider TradesFebruary 22, 2024 | finanznachrichten.deC4 Therapeutics, Inc.: C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsFebruary 22, 2024 | finance.yahoo.comC4 Therapeutics Inc (CCCC) Reports Full Year 2023 Financial Results and Business UpdatesSee More Headlines Receive CCCC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for C4 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today5/01/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CCCC CUSIPN/A CIK1662579 Webwww.c4therapeutics.com Phone617-231-0700FaxN/AEmployees145Year FoundedN/APrice Target and Rating Average Stock Price Target$10.25 High Stock Price Target$20.00 Low Stock Price Target$2.00 Potential Upside/Downside+56.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-132,490,000.00 Net Margins-638.34% Pretax Margin-632.17% Return on Equity-55.30% Return on Assets-35.80% Debt Debt-to-Equity RatioN/A Current Ratio6.34 Quick Ratio6.34 Sales & Book Value Annual Sales$20.76 million Price / Sales21.62 Cash FlowN/A Price / Cash FlowN/A Book Value$4.07 per share Price / Book1.61Miscellaneous Outstanding Shares68,601,000Free Float63,134,000Market Cap$448.65 million OptionableOptionable Beta3.18 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Andrew J. Hirsch M.B.A. (Age 53)CEO, President & Director Comp: $971kDr. Kenneth C. Anderson M.D. (Age 73)Ph.D., Co-Founder, Independent Director & Member of Scientific Advisory Board Comp: $39.03kDr. Stewart Fisher (Age 57)Chief Scientific Officer Comp: $657.34kMr. Scott N. Boyle M.B.A. (Age 46)Ph.D., Chief Business Officer Comp: $672.78kDr. Nathanael S. Gray Ph.D.Co-Founder & Member of Scientific Advisory BoardMs. Kendra AdamsChief Financial OfficerMr. Mark Mossler (Age 51)Chief Accounting Officer Ms. Jolie M. Siegel J.D. (Age 47)Chief Legal Officer & Corporate Secretary Comp: $610.4kMs. Kelly A. Schick (Age 44)Chief People Officer Dr. Isabel Chiu Ph.D.Senior Vice President of Strategic Alliances & Business DevelopmentMore ExecutivesKey CompetitorsEditas MedicineNASDAQ:EDITVoyager TherapeuticsNASDAQ:VYGRFate TherapeuticsNASDAQ:FATELexeo TherapeuticsNASDAQ:LXEOTaysha Gene TherapiesNASDAQ:TSHAView All CompetitorsInstitutional OwnershipMirae Asset Global Investments Co. Ltd.Bought 41,445 shares on 5/1/2024Ownership: 0.060%Wasatch Advisors LPSold 2,810,470 shares on 4/18/2024Ownership: 6.310%Wasatch Advisors LPBought 891,808 shares on 2/14/2024Ownership: 14.487%Bellevue Group AGBought 62,000 shares on 2/14/2024Ownership: 0.126%Lighthouse Investment Partners LLCBought 21,981 shares on 2/14/2024Ownership: 0.045%View All Institutional Transactions CCCC Stock Analysis - Frequently Asked Questions Should I buy or sell C4 Therapeutics stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for C4 Therapeutics in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CCCC shares. View CCCC analyst ratings or view top-rated stocks. What is C4 Therapeutics' stock price target for 2024? 6 Wall Street research analysts have issued 1-year price targets for C4 Therapeutics' stock. Their CCCC share price targets range from $2.00 to $20.00. On average, they predict the company's stock price to reach $10.25 in the next twelve months. This suggests a possible upside of 59.4% from the stock's current price. View analysts price targets for CCCC or view top-rated stocks among Wall Street analysts. How have CCCC shares performed in 2024? C4 Therapeutics' stock was trading at $5.65 at the beginning of the year. Since then, CCCC stock has increased by 13.8% and is now trading at $6.43. View the best growth stocks for 2024 here. Are investors shorting C4 Therapeutics? C4 Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 9,150,000 shares, an increase of 73.0% from the March 15th total of 5,290,000 shares. Based on an average trading volume of 3,740,000 shares, the days-to-cover ratio is presently 2.4 days. View C4 Therapeutics' Short Interest. When is C4 Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our CCCC earnings forecast. How were C4 Therapeutics' earnings last quarter? C4 Therapeutics, Inc. (NASDAQ:CCCC) posted its quarterly earnings results on Thursday, February, 22nd. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by $0.01. The firm had revenue of $3.26 million for the quarter, compared to the consensus estimate of $5.23 million. C4 Therapeutics had a negative net margin of 638.34% and a negative trailing twelve-month return on equity of 55.30%. When did C4 Therapeutics IPO? C4 Therapeutics (CCCC) raised $150 million in an initial public offering (IPO) on Friday, October 2nd 2020. The company issued 8,800,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI, BMO Capital Markets and UBS Investment Bank served as the underwriters for the IPO. Who are C4 Therapeutics' major shareholders? C4 Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Wasatch Advisors LP (6.31%), Mirae Asset Global Investments Co. Ltd. (0.06%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Adam Crystal, Andrew Hirsch, Elena Prokupets, Jolie Siegel, Malcolm Salter, Stewart Fisher and Utpal Koppikar. View institutional ownership trends. How do I buy shares of C4 Therapeutics? Shares of CCCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CCCC) was last updated on 5/1/2024 by MarketBeat.com Staff From Our Partners😱 This phenomenon is smashing regular market gainsMillPubDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyForget Nvidia. This is the future of AIPorter & CompanyBiden out June 13; Kamala won’t replace him?Paradigm PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing4 coins to be the “Next Bitcoin”True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C4 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
